Forbes reports FDA struggling to police growing peptide market
The piece examines enforcement gaps as compounded and research-labeled peptides spread faster than the agency's capacity to act.
DO
By Daniel Okafor · Regulatory Correspondent
Oct 9 10:50 ETSource: Forbes
The wire
- 01Forbes reports that the FDA is having difficulty policing the expanding market in peptide products sold through compounders, clinics and research-chemical channels.
- 02Clinicians and pharmacists working with peptides face a market where enforcement is uneven, raising questions about product sourcing and legal exposure.
- 03The article is journalism rather than an agency announcement; no new FDA rule, warning letter or category decision is attached to it.
From the source
Read at forbes.comThe FDA Is Struggling To Police The Peptide Boom
